GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines, today highlighted the strategic positioning of its oncology asset Gedeptin® (Ad/PNP) in the context of accelerating industry investment in next-generation in vivo cancer therapies. The company believes Gedeptin is uniquely positioned to address the central challenge of immunologically 'cold' tumors that limit the effectiveness of even the most advanced therapeutic modalities.
Recent high-profile transactions and investments across the biopharmaceutical sector underscore a growing focus on therapies designed to simplify delivery, improve scalability, and expand therapeutic reach. As these approaches advance, the ability to positively modify the local tumor environment is believed to be a critical determinant of clinical success. Gedeptin, a gene-directed enzyme prodrug therapy (GDEPT) delivered intratumorally, is designed to directly destroy both proliferating and non-proliferating tumor cells within the treated tumor, while also demonstrating high bystander activity due to the diffusion of the in situ generated cytotoxic agent into neighboring tumor cells.
In vivo preclinical experiments have shown Gedeptin treatment to be additive or synergistic with checkpoint blockade-type agents. Studies in preclinical in vivo tumor models of metastasis have demonstrated that treatment of a single lesion can robustly sensitize tumors to checkpoint blockade inhibitors. This effect is presumably achieved by destroying tumor tissue, including the tumor microenvironment, exposing neoantigens, and enhancing immune response and activity of immune checkpoint inhibitors (ICIs) at distant, untreated lesions. This dual mechanism—localized cytotoxicity combined with enhanced immune response—has the potential to offer an improved therapeutic approach to addressing solid tumor metastatic disease.
GeoVax has generated preclinical, clinical, and translational data supporting Gedeptin's ability to induce localized tumor cell death against both proliferating and non-proliferating tumors while minimizing systemic toxicity, and to potentially improve response rates when combined with immune checkpoint inhibitors. As checkpoint inhibitors continue to move earlier in treatment paradigms, including neoadjuvant and first-line settings, the need for complementary approaches that enhance response rates is becoming increasingly evident.
The company is advancing Gedeptin in combination with checkpoint inhibition in a planned Phase 2 clinical trial in first-line head and neck cancer therapy, with additional solid tumor indications under evaluation. 'Checkpoint inhibitors have transformed cancer care, but many patients still do not achieve durable responses,' said Kelly T. McKee, M.D., Chief Medical Officer of GeoVax. 'We believe Gedeptin is well positioned as a combination-enabling platform designed to enhance therapeutic response across checkpoint inhibitors and other emerging oncology modalities.'
Gedeptin has received Orphan Drug Designation for oral and pharyngeal cancers. The company continues to evaluate strategic partnerships and collaborations to advance the clinical development and potential commercialization of Gedeptin-based combination therapies. For more information, visit www.geovax.com.
